Morrisville, NC, August 28, 2025—Lightship Inc., the clinical research site organization dedicated to increasing access and choice for sponsors and participants, today announced its collaboration with The Society for Clinical Research Sites (SCRS) as a Global Impact Partner (GIP). As a GIP, Lightship will participate on the GIP Board, working closely with SCRS’ Leadership Council to champion sites within the global research marketplace. 

“Sites are the foundation of every clinical trial, and when sites are strong, participants and sponsors benefit,” said Michael Shipton, Chief Business Officer for Lightship. “We are thrilled to collaborate with SCRS as a Global Impact Partner and look forward to advancing site sustainability and enabling trials that are more inclusive, accessible, and effective for everyone involved.”

Through its commitment to making clinical research participation possible for all, Lightship offers a flexible, accessible site model that expands reach and helps bring new therapies to market faster. By meeting participants where they are—in brick-and-mortar clinics, in their own homes, and through mobile and virtual options—Lightship reduces barriers to enrollment while providing sponsors with reliable, high-quality delivery. This approach accelerates enrollment, strengthens retention, and improves representation through a single trusted partner. 

As a Global Impact Partner, Lightship will collaborate with SCRS leadership to shape industry best practices, advocate for greater site sustainability, and improve the research experience for both participants and sponsors.

“We are excited to welcome Lightship as a Global Impact Partner,” said Marcus Maleck, Vice President, Global Business Partnerships for SCRS. “Their flexible, patient-centered site model aligns with our mission to strengthen sites and expand access to research. Together, we can advance sustainability, equity, and collaboration across the global research community.”

To learn more about Lightship and how its site network model provides a seamless experience for sponsors and participants, visit www.lightship.com or follow the company on LinkedIn.

Lightship, Inc. is a clinical trial site organization committed to making research participation possible for all. We collaborate with biopharmaceutical companies and CROs to design and conduct studies that accelerate the development of new therapies while expanding access and choice. As a tech-agnostic partner, we integrate with sponsors’ preferred platforms and workflows. Our model meets people where they are, supporting participants throughout their clinical trial journey, from initial engagement to study completion. We make participation easy, convenient, and safe through flexible visit options, including in clinics, at home, and on our mobile research units. By transforming the clinical research experience, we aim to shorten study timelines, enhance diversity, improve retention, and ultimately help bring better treatments to market faster. Learn more at www.lightship.com.

About the Society for Clinical Research Sites (SCRS) 

The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites in 50+ countries, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs.org.  Our voice. Our community. Your success.

Contact: Brittany Kearns
Phone: 571-271-7211
Email: brittany@crossroadsb2b.com

The collaboration reflects a shared mission to amplify site sustainability and advance equity in clinical trial access.

Lightship Joins SCRS Global Impact Partner Program 

Circuit Clinical Solutions Inc. [“Circuit Clinical”] and Lightship Inc. [“Lightship”] Mutually Agree to Terminate Merger Agreement.

Circuit Clinical and Lightship today announced that they have mutually decided to terminate the previously announced merger agreement between the two companies. This decision was reached following careful consideration of recent developments and a thorough review of strategic priorities.

While both organizations entered the agreement with a shared vision for future growth and innovation, changes in market dynamics and evolving business needs have led to the conclusion that continuing independently is in the best interest of their respective stakeholders.

“We deeply value the relationship we’ve built with Lightship and are proud of the collaborative efforts made throughout this process,” said Dr. Irfan Khan, CEO of Circuit Clinical. “Circuit Clinical remains committed to driving value for shareholders and delivering best-in-class solutions to our customers.”

David MacMurchy, CEO of Lightship echoed the sentiment, stating, “Although our paths will diverge, we maintain great respect for the Circuit Clinical team and look forward to continued success in our individual journeys.”

The companies will continue to operate as separate entities and remain focused on their respective missions and long-term objectives.

About Circuit Clinical
Circuit Clinical, one of the fastest-growing research networks in the USA, is dedicated to empowering patients to choose clinical research as a care option through improved access to clinical trials. Committed to transforming the experience of finding, choosing, and participating in clinical research for physicians and their patients, Circuit provides clinical research services through traditional, hybrid, and decentralized community-based site models and their MD Prescreen service that optimizes patient referrals. Learn more at www.circuitclinical.com.   

About Lightship
Lightship is a clinical trials service provider focused on increasing access and ensuring research reflects representative populations. We partner with biopharma, CROs, and academic institutions to design and deliver studies that engage diverse and underserved patient groups, accelerating enrollment while improving patient access in clinical trials.   

Through targeted outreach and education, we connect with potential participants in their community, building trust and reducing barriers to enrollment. Our virtual and hybrid trial models, supported by our site network, mobile research units (MRUs), and mobile nursing, allow patients to participate in research that fits their lives, whether at home, in a clinic, or at an MRU in the community.   

By making trials more accessible and patient-centered, we reduce enrollment timelines, improve retention, and accelerate the development of therapies that better reflect real-world communities. Learn more about us at www.lightship.com.   

Contact:
Michael W. Shipton
Chief Commercial Officer, Lightship
mshipton@lightship.com | +1 919-605-8064

Circuit Clinical and Lightship today announced that they have mutually decided to terminate the previously announced merger agreement between the two companies.

Circuit Clinical and Lightship Mutually Agree to Terminate Merger Agreement

Discover how Lightship’s hybrid clinical trial model successfully accelerated enrollment for a Phase III cardiovascular study while expanding access, choice, and equity. Partnering with a top 10 global pharmaceutical company, Lightship leveraged its curated site network and experienced mobile research nurses to deliver a seamless trial experience that reduced patient burden and expanded reach.

By integrating in-clinic and off-site visits, Lightship enabled participation from individuals living over 60% farther from study sites than typical participants. This approach not only boosted enrollment capacity but also improved participant diversity - engaging more Black, African American, Hispanic, and Latino individuals than the national average for cardiology trials.

Through patient-centric design and strong operational alignment with site teams, Lightship ensured consistent oversight, high retention rates, and a smooth transition between visit modalities. The result was an accelerated recruitment timeline that exceeded sponsor goals and enhanced the overall participant experience.

How hybrid trial design expands reach and participant representation

The critical role of our site network and mobile nurses in accelerating enrollment

Strategies for enhancing diversity and retention

Key outcomes, including a 60% increase in participant distance and 95% retention for off-site visits

Hydrid Case Study.pdf

Download Hybrid Case Study

Discover How Lightship’s Curated Site Network and Mobile Research Nurses Accelerated Enrollment in a Phase III Cardiovascular Study

Circuit Clinical Solutions Inc. [“Circuit Clinical”] and Lightship Inc. [“Lightship”] Announce Strategic Merger to Accelerate Scale and Expanded Access in Clinical Research

Buffalo, NY & Morrisville, NC— Today, Lightship and Circuit Clinical proudly announce their strategic merger, forming a leading, unified force in clinical trial delivery. This landmark collaboration represents a significant step toward consolidating a fragmented industry—establishing a new standard for scale, accessibility, and innovation.

By uniting complementary capabilities, deep therapeutic expertise, and cutting-edge delivery models, the combined organization is purpose-built for growth and long-term impact. Bringing together Lightship’s leadership in hybrid trial models and mobile care with Circuit Clinical’s trusted community-based site network and patient engagement strengths, the new entity offers an integrated solution for sponsors, CROs, healthcare systems, and—above all—patients. Together, they are uniquely positioned to expand access, accelerate timelines, and enhance the overall clinical trial experience.

“Together, we’re redefining what’s possible in clinical research,” said David MacMurchy, CEO of Lightship. “This is an exciting milestone for our teams and for the industry as a whole.  Together, we will reframe what’s possible in clinical research—delivering greater value to sponsors and better outcomes for patients everywhere.”

“This merger is more than a business combination; it’s a bold response to the evolving needs of clinical research,” said Dr. Irfan Khan, CEO of Circuit Clinical. “Lightship plus Circuit Clinical delivers the scale, trust, and innovation needed to meet the growing complexity of modern trials”

Expanded Reach through physical site networks and remote delivery capabilities

Flexible Participation Models supporting traditional, hybrid, and fully virtual trials

Scalable, Professionally Managed Infrastructure that simplifies execution and accelerates patient enrollment

Streamlined Services that enhance the experience for investigators, health systems, sponsors, and CROs

By combining proven delivery models with top-tier operational talent, the merged company is setting a new bar for the future of clinical trials.

Mr. MacMurchy and Dr. Khan will serve as co-CEOs of the new organization. Both Circuit Clinical and Lightship will continue to operate under their existing brands during the transition. The combined company’s new name and identity will be announced in the coming weeks.

Media Contacts:
Michael W. Shipton
Chief Commercial Officer, Lightship
mshipton@lightship.com | +1 919-605-8064

Candice Kent
VP Marketing and Communications, Circuit Clinical
ckent@circuitclinical.com | +1 484-885-0981

Today, Lightship and Circuit Clinical proudly announce their strategic merger, forming a leading, unified force in clinical trial delivery.

Lightship’s MRUs bring clinical trials directly to participants, overcoming barriers and enhancing engagement. They offer a convenient, patient-focused approach to clinical trials in a trusted environment close to home.

With an experienced clinical team on board and customizable equipment tailored to each study’s needs, our MRUs deliver seamless care, from engagement and pre-screening to study visits and assessments in the community. Our units are fully equipped to collect biospecimen samples, store IMP under secure and temperature-controlled conditions, conduct ECGs, monitor vitals, perform physical exams, and support a wide range of clinical trial activities.

How MRUs help with community outreach - including targeted study outreach and long-term engagement; pre-screening; and study visits

Our collaborative approach to community outreach and the results that have stemmed from our workflow

Novel approaches to MRU incorporation to make your study a success

Lightship MRU Case Study.pdf

Download MRU Case Study

Mobile Research Units in Action: Discover how Lightship's MRUs bring clinical trials directly to communities, enhancing patient engagement and simplifying trial delivery.

David MacMurchy, Chief Executive Officer at Lightship, offers some insights into the company's mission toward improving equity and diversity in clinical trials.

Accelerate Inclusive Enrollment and Delivery with Lightship

Sepehr Shojaei, VP of Design Solutions at Lightship, talks about how the company works with pharma and contract research organization (CRO) partners to support clinical trials that are patient-first and accessible.

Lightship’s Approach to Accessible, Representative, and Impactful Clinical Trials

EL SEGUNDO, Calif., March 27, 2025 – Lightship Inc., a leading provider of community-based, decentralized clinical trial services, is pleased to announce the appointment of Michael Shipton as Chief Commercial Officer (CCO). With a proven track record of driving growth and innovation in the life sciences and technology sectors, Shipton will play a key role in reshaping Lightship’s go-to-market strategy and strengthening its ability to meet the growing complexity of representative clinical trials.

Shipton brings over 30 years of experience in designing and executing high-impact business solutions, with expertise across sales management and operations, marketing, strategic pricing and partnerships, finance, global operations, and customer engagement. As Lightship enters an exciting new phase of growth, his leadership will be essential in expanding the company’s service offerings and driving strategic business development efforts that will enable Lightship to meet the evolving needs of its clients.

“Michael’s appointment comes at a critical juncture in Lightship’s growth,” said David MacMurchy, CEO of Lightship. “His extensive experience working in both the CRO and site spaces, combined with his ability to solve complex client challenges, makes him the ideal leader to strengthen our market positioning. Michael’s strategic vision, proven ability to drive business growth, and commitment to patient-centered solutions will be instrumental in helping us expand our reach to more clients—and ultimately more patients—enhancing our impact across the industry.”

Shipton has held senior leadership positions at some of the most recognized names in the industry, including Profound Research, Science 37, Syneos Health, and Quintiles (now IQVIA), where he led significant go-to-market transformations, drove sales growth, and oversaw cross-functional teams to achieve commercial excellence. His proven track record and passion for improving health outcomes will be critical to driving Lightship’s mission forward with even greater impact.

“I have always believed in the transformative power of clinical trials to improve health outcomes, and I’m excited to join Lightship during this pivotal period of growth,” said Shipton. “I look forward to collaborating with the team to advance Lightship’s mission, reach more patients, and develop solutions that address the complexities facing clinical trials today. Together, we can continue to make trials more accessible, inclusive, and impactful for individuals and communities everywhere.”

Lightship Inc. is a clinical trials service provider focused on increasing access and ensuring research reflects representative populations. We partner with biopharma, CROs, and academic institutions to design and deliver studies that engage diverse and underserved patient groups, accelerating enrollment while improving patient access in clinical trials.

Through targeted outreach and education, we connect with potential participants in their community, building trust and reducing barriers to enrollment. Our decentralized and hybrid trial models, supported by our site network, mobile research units (MRUs), and mobile nurses allow patients to take part in research that fits their lives, whether at home, in a clinic, or at an MRU in the community.

By making trials more accessible and patient-centered, we reduce enrollment timelines, improve retention, and accelerate the development of therapies that better reflect real-world communities. Learn more about us at: www.lightship.com.

Lightship Inc., a leading provider of community-based, decentralized clinical trial services, is pleased to announce the appointment of Michael Shipton as Chief Commercial Officer (CCO).

Lightship Appoints Michael Shipton as Chief Commercial Officer to Accelerate Growth and Market Leadership

EL SEGUNDO, Calif. – March 20, 2025 – Lightship, a leading provider of community-based, decentralized clinical trial services, is appointing Darcy Forman as Chief Operating Officer (COO). In this key role, Forman will further enhance Lightship’s ability to deliver representative clinical trials at scale, driving operational excellence, and expanding the company’s capacity to handle more complex, decentralized trial solutions in communities across the nation.

Forman joins Lightship with over 25 years of distinguished experience in clinical research, blending deep expertise in clinical operations with a strategic approach to corporate development. Throughout her career, she has been passionate about innovation in clinical trials, particularly decentralized models that increase patient accessibility and engagement. Forman’s extensive background in both operations and strategic leadership will be critical to strengthening Lightship’s ability to deliver on its mission and grow to serve evolving client needs.

“We are thrilled to welcome Darcy to the Lightship team,” said David MacMurchy, CEO of Lightship. “With her proven track record of leading complex clinical operations, delivering both traditional and decentralized trials, Darcy will be a key driver in our next phase of growth. Her leadership will empower us to push the boundaries of what we can do in the community, ultimately helping reduce enrollment timelines, improving retention, and ensuring trials better reflect representative communities”

Forman’s most recent role was as an executive consultant where she worked with a variety of companies across the clinical research spectrum to address strategic needs. Prior to that, she served as the Chief Delivery Officer at Science 37, where she oversaw clinical operations service delivery, including patient engagement, clinical operations, data management, and nursing solutions. She has also held leadership positions at well-regarded CROs, including i3 Research (now Syneos Health), Health Decisions, Clinipace, and Firma Clinical. Forman began her career as a bench scientist at Pfizer Pharmaceuticals before transitioning into Pfizer’s clinical research division, where she gained valuable experience in clinical operations and project management.

“I am ecstatic to be joining Lightship at such a key time,” said Darcy, “I am confident in our abilities to expand access for clinical trials, and I am so excited to join a new team where I can continue to expand the mission.”

As COO, Forman will focus on optimizing Lightship’s operational infrastructure, implementing best practices, and building a scalable foundation to support future strategic growth. Her leadership will ensure that the company continues to deliver seamless and effective solutions at scale, meeting the evolving needs of clients and patients.

Lightship is a clinical trials service provider focused on increasing access and ensuring research reflects representative populations. We partner with biopharma, CROs, and academic institutions to design and deliver studies that engage diverse and underserved patient groups, accelerating enrollment while improving patient access in clinical trials.

Through targeted outreach and education, we connect with potential participants in their community, building trust and reducing barriers to enrollment. Our decentralized and hybrid trial models, supported by our site network, mobile research units (MRUs), and mobile nursing, allow patients to take part in research that fits their lives whether at home, in a clinic, or at an MRU in the community.

By making trials more accessible and patient-centered, we reduce enrollment timelines, improve retention, and accelerate the development of therapies that better reflect real-world communities. Learn more about us at: www.lightship.com.

Lightship, a leading provider of community-based, decentralized clinical trial services, is appointing Darcy Forman as Chief Operating Officer (COO)

Lightship Appoints Darcy Forman as Chief Operating Officer to Accelerate Expansion and Operational Excellence

At SCOPE 2025, David MacMurchy, CEO of Lightship, and Tim Joy, Head of Strategic Solutions, Information Management at Pfizer, shared their insights on how thoughtful collaboration and innovative trial models can help address long-standing challenges in clinical research.

The ongoing need for greater representation in clinical trials

How intentional, community-based engagement is driving meaningful progress

The sponsor’s role in building scalable, sustainable solutions

Strategic deployment of tools like mobile research units, home visits, and virtual components

Real-world case studies showcasing the impact of Lightship and Pfizer’s partnership

Lighthsip Pfizer SCOPE Conversation

At SCOPE 2025, Ligthship CEO David MacMurchy and Pfizer Head of Strategic Solutions Tim Joy discuss the industry challenge and where more needs to be done.

Implementing FDA Guidance Using Next-Gen Approaches to Representative Clinical Trial Recruitment & Design

Building a successful clinical research start-up is a high stakes endeavor, regardless of fluctuations in funding, the geopolitical climate, and macroeconomic headwinds. How can companies bring novel, innovative solutions that benefit investors, sponsors, investigators, and patients, and how can leaders work toward sustainable growth? The answer may be as simple (or complex) as business fundamentals.

Gain insights from Lightship’s co-founder, Samantha Eells, and CEO, David MacMurchy, on what a strong start-up needs to succeed. Read the full article in pharmaphorum.

Get insights from Lightship’s experts on the factors that drive long-term success for clinical research start-ups.

Which Companies Will Last? Success Begins With the Basics

Season of Giving 2023: An Inspiring Beginning

In 2023, Lightship and Acclinate launched our first annual Season of Giving — and it was a resounding success! Lightship and Acclinate are partnered to lead the way in offering more inclusive clinical trials by engaging people where they are. The first step to meaningful and trusted relationships with the people and communities we engage, is to give back to the communities we live and work in everyday​.

To honor the communities we serve, during November and December our teams across the United States volunteered their time to help the people and communities who give so much to us in clinical research.

“Lightship and Acclinate partnered to improve health equity in clinical research,” says Lightship Co-Founder Samantha Eells, “and by coming together to do the Season of Giving, we’re able to give back to the communities that give to us.”

We had fun and made a positive impact. Here’s a snapshot of the impact we made together.

In Birmingham, Lightship and Acclinate actively participated in a local initiative. Our teams came together at the Bush Hills Community Garden & Urban Farm, not just to volunteer, but to make a direct impact. We worked at the garden and helped distribute its fresh produce to local residents, directly supporting the health and wellness of the community.

This hands-on effort was matched by our involvement in the Bush Hills Community Holiday Gala, where we played a supporting role in bringing holiday cheer to the neighborhood.

Senior Director of Business Development Kyle Ashe of Acclinate summarizes our shared mission, “Our strategic partnership with Lightship is about improving access and education. Together, we’re not only pursuing business success, we’re committed to giving back to the community.” This sentiment fueled our actions as we invested our time and resources to support those around us.

Through these endeavors, Lightship and Acclinate have demonstrated a commitment to community engagement that goes beyond business as usual, reflecting a genuine dedication to the people who are at the heart of clinical research.

In November 2023, Lightship and Acclinate volunteered at the Los Angeles Regional Food Bank to help combat hunger. Sepehr Shojaei, VP of design solutions at Lightship, shared his thoughts: “Typically, our work with Acclinate is in reaching underserved populations in the clinical trial space and increasing access and choice. We wanted to work with them in giving back to our communities and supporting those who have supported us throughout the year.”

That day, our teams assembled 1,257 food packages for Los Angeles County families.

These packages are vital, as the LA Food Bank plays a key role in feeding those in need, delivering meals through local organizations and direct programs.

Samantha Eells, co-founder of Lightship, shared her perspective: “At the food bank today, we’re putting together packages of food to give to different folks across L.A. County. Lightship’s mission is to improve access and choice in clinical research, and overall drive better health equity for all. By giving back to the communities that serve us, this helps improve the engagement around how we work with the people who give to us in volunteering their time in clinical research.”

This day of service went beyond volunteering; it was a clear demonstration of our core values, showing our dedication to enhancing health outcomes and the well-being of the communities we serve.

Lightship-Season-of-Giving-LA_VF

In December 2023, our teams supported the Food Bank of Central & Eastern North Carolina’s efforts to reduce hunger:

This food bank serves 34 counties and distributes 2 million pounds of food per week

600,000 people in the region experience food insecurity — half of which are kids and teens, with the second largest group being senior citizens

Food goes from the Raleigh distribution center to partner agencies/nonprofits like food kitchens and schools, as well as directly to families in need

During our volunteer shift we helped pack 19,515 pounds of sweet potatoes — equivalent to 16,292 meals! 

Kim Rose, Lightship VP of legal operations and one of the volunteers, emphasized the importance of the initiative, “This is the first year that Lightship is doing a Season of Giving, and we’re all very excited about it, and partnering with our friends at Acclinate to do this. ... It feels really important to be involved in the community and to give back when we can. Community involvement and community engagement is critical to everything that we’re trying to achieve as a company. It aligns with our goals and our mission to expand access, increase diversity in clinical trials, and just be a bigger and better part of our communities.”

Kyle reinforced the collaborative spirit, “A big piece of what we’re doing at Acclinate — and at Lightship, too,” says Kyle, “is community engagement work. ... Let’s use our hands together. This is how you create partnerships.”

This initiative has allowed Lightship and Acclinate to offer vital support and reinforce our commitment to community and collaboration, central to our missions.

lightship-season of giving- raleigh_vF

In addition to the major city events hosted by Lightship and Acclinate, we had many team members who don’t live near one of these hub cities step up to create Season of Giving contributions of their own:

In Washtenaw County, MI, a team member participated in a weeklong event in collaboration with Kroger and Food Gatherers to raise donations for 1 million meals to feed food insecure families

In Orange, NJ, a team member volunteered with Friends of Metcalf Park cleaning up and repainting park benches

In Napa, CA, team members delivered 25 meals to homebound seniors

In Tampa Bay, FL, a team member volunteered for a mobile pantry called Feeding Tampa Bay

Every contribution, big or small, plays a crucial role in our Season of Giving, allowing every team member to join our mission of community support.

Lightship and Acclinate plan to continue Season of Giving events in 2024 and beyond and have invited additional health-focused and clinical trial industry partner companies to join in this effort.

“At Lightship, we spend every day trying to incrementally make the lives of our patients better by the way that we’re delivering clinical trials,” says Ellie Stewart, senior manager of design solutions. “What’s special about the Season of Giving is that generosity goes a long way and creates a positive cycle that impacts everyone’s life — not just the patients that we’re serving. … I love our partnership because it’s creating this positive cycle … for giving back and making sure we’re very community forward and community focused.”

Contact us if you’d like to be part of our next Season of Giving days of service. Together, we can make an annual impact on the communities that give their time to research.

Season of Giving 2023: An Inspiring Start

Rethinking Clinical Trial Community Engagement Through an End-to-End
Collaborative Approach

It’s no secret that improving clinical trial participation is essential, and it takes intentional
effort and careful planning to bring this goal to fruition. Rethinking how we approach
community engagement, with a focus on collaboration, can help drive results and build trust
in underserved communities.


In this presentation from Lightship’s Sepehr Shojaei and Acclinate’s Shayla Wilson,
discover:

Novel, collaborative approaches to community engagement for clinical trials, starting
from the top of the research funnel

Case studies that demonstrate the success of our efforts in improving trial access,
inclusion, and equity

Examples of innovative education and outreach strategies, from mobile research
units (MRUs) to community volunteering

Explore Lightship’s collaboration with Acclinate and our approach to clinical trial engagement in this presentation.

Scope 2024 Video

Rethinking Clinical Trial Engagement Through Collaboration

Lightship was thrilled and honored to participate in the 13th annual PharmaTimes Clinical Researcher of the Year – The Americas Awards. This competition included talented individuals and groups from across the pharmaceutical and life science industries, and Lightship’s Colleen Butler and Rachel Palumbo took home the GOLD prize for the startup team category. 

Check out this article in PharmaTimes for a recap of the event and a full list of winners. Congrats to all the finalists and champions! 

Start Up Team of the Year 2023 – The America's

This November and December, Lightship and Acclinate are working together on something new: their first annual Season of Giving. The two companies work together to provide more access and choice to patients, and to improve health equity in clinical research. Now, they are also teaming up to donate time and support to the communities where they live and work by encouraging team members to contribute to meaningful local causes.  

·      Los Angeles Regional Food Bank 

·      Bush Hills Community Garden & Urban Farm

·      Food Bank of Central & Eastern North Carolina

“This holiday season, we are giving back to communities that support us,” Lightship founder, Samantha Eells, explains. “People are the ones who make clinical research and advances in medicine possible, and we’re committed to giving back to them. That’s what this Season of Giving series of events with our partner Acclinate is all about — and we’d love to have even more clinical research industry companies participate.” 

Acclinate Chief Development Officer & Co-Founder, Tiffany Whitlow, is equally delighted to lead the Season of Giving: “By directly giving back to people in our communities in collaboration with Lightship and our community partners, we are continuing to bring our vision to life. We’re focusing on those most in need while honoring the communities that give to all of us.”

Lightship and Acclinate are extending an open call for other organizations interested in giving back to partner with them in future events. Use the contact information at the end of this announcement if interested. 

Lightship & Acclinate Season of Giving FAQ

What was the inspiration behind this first annual Season of Giving partnership?

 Lightship and Acclinate partnered to support more inclusive clinical trials that engage people where they are. An important part of engaging with and supporting communities that take part in clinical research is to give back in an ongoing way. This first Season of Giving is an expansion of Acclinate and Lightship working together to do more to support their communities.

“With Lightship celebrating our 5th birthday and this season being the 1-year anniversary of the Lightship-Acclinate partnership, it was the perfect time for us to plan to give back to the communities we live and work in every day,” says Samantha Eells.

Is there a long-term plan for community service and giving back?

Lightship has established The Lightship Giving Group, which will continue to offer quarterly support to community organizations year-round. 

“We plan to learn and grow from this first annual Season of Giving event series and go on to build programmatic support, engaging and giving back to our communities on an ongoing basis,” Eells says.

Acclinate, a digital health company for health equity, focuses on continuous and sustained community engagement for communities of color through their NOWINCLUDED community platform. This Season of Giving is yet another moment of service to support their communities. 

How did you select the organizations for the first annual Season of Giving?

“One in four people in the U.S. do not have enough food to eat — especially during the holidays,” Eells shares. “Volunteering at local food banks is one way to provide more hope for all, in alignment with Lightship’s mission.

Acclinate and Lightship also support the Bush Hills Community Garden and Urban Farm in Birmingham, which provides produce for their community while offering education for all to learn more about how to plant, cultivate, grow, harvest, prepare, and preserve to provide food. 

“We’re continuously investing in and empowering our Birmingham community to take charge of their own health by providing spaces for education, good nutrition, physical activity, and wellness,” says Whitlow. “In this Season of Giving — and all seasons — we want to invest in the places where many of our team and NOWINCLUDED members live, work, and play.”

How can my company partner with Lightship and Acclinate for this Season of Giving or future community volunteer events?

Acclinate and Lightship encourage the clinical research industry and health-focused organizations to join them in giving back to their communities. Use the contact information at the bottom of this news release to connect.

About Lightship: Lightship Inc. is a clinical trials service provider focused on increasing access and choice in taking part in research to improve equity for all. We design and conduct studies in partnership with biopharmaceutical companies to accelerate bringing new therapies to market. Our approach is to engage people where they are and support them across their journey in a clinical trial, from first contact to study completion. We work to make it easy, convenient, and safe for people to take part by offering visits in clinic, at home, using our mobile research units, and via digital health tools. By transforming the way we conduct clinical research, we can decrease study timelines, expand access, increase inclusion, and increase retention to accelerate development of better therapies. Learn more at Lightship.com, and follow us on LinkedIn.

About Acclinate: Acclinate is a digital health startup that is working to improve health equity through predictive analytics technology and community engagement. We specialize in accessing and engaging communities of color so they can make informed health decisions and learn about clinical trial participation. Through our online platform, NOWINCLUDED, we provide education, resources, and research opportunities to our community members. Learn more at Acclinate.com.

Lightship & Acclinate Season of Giving: Donating Time to Communities That Support Clinical Research

Join Medable, GSK, and Lightship's Sepehr Shojaei for a panel discussion on how a trial platform as a service can enhance, expedite, and improve the day-to-day operations of clinical operations across the life cycle of a study.  

Keeping Up with ClinOps: Why and How to Improve Delivery

Only 20% of clinical trial participants are people of color. Less than 45% of participants are women.1 At the same time, the FDA commissioner recently described “meaningful representation” in clinical research as “fundamental to public health.” 

The divide between current clinical research practices and those that effectively promote diversity is growing, due in large part to our increased awareness of what works and what doesn’t — what encourages broad participation and what discourages minorities from engaging with the process. That said, there is a critical difference between awareness and action. While many organizations may think it is important to create more inclusive clinical trials, they often lack the resources and the know-how to insert meaningful measures of equity and diversity into their trial design and execution.

In response, the Digital Medicine Society (DiME) has teamed up with industry leaders like Lightship and Acclinate to offer insight, support, and practical resources through the Diversity, Equity, & Inclusion Initiative. These resources are designed to provide actionable steps for transforming your approach to clinical research, and they are the beginning of creating trials that are person-centered and fitted for the future.

Now is the ideal time to take action against the lack of diversity in clinical research. Why? First, the representation gap is only growing the more we learn about the vulnerabilities of certain populations, making it increasingly paramount to align our research practices with our cultural realities. For example, Black Americans account for over 35% of kidney failure in the United States, while the number of Latino with kidney failure has increased by 70% in the past two decades.2 Unfortunately, these numbers are not represented in the populations actually participating in research, with less than 10% of both Black Americans and Hispanic Americans enrolled in clinical trials.1

These realities are rooted in mistrust, which is itself the product of years of unethical research and unfair treatment against people of color. Even today, many racial and ethnic minority groups (REMGs) don’t have access to quality healthcare, let alone the time and information to participate in clinical trials. This inequality is further reinforced by the troublesome logistics that often plague underserved neighborhoods and communities, such as a lack of public transportation or overall health literacy.

Additionally, modern technology is making it more feasible than ever to address these gaps in representation. Virtual participation in healthcare is at an all-time high with nearly 40% of U.S. adults taking part in telemedicine, and digitization is creating new options in nearly every corner of the clinical research process3: 

Clearly, technology is opening up many new doors in clinical research. That said, it is important that some of these new doors lead to greater diversity, and this confluence of urgency and ability is exactly what inspired Lightship’s collaboration with DiME.

The Diversity, Equity, & Inclusion Initiative offers the insight and digital tools necessary for developing person-centered strategies that increase representation in clinical trials. DiME encourages organizations to approach every clinical trial and patient community as part of a three-step process:

Lightship and Acclinate worked incollaboration with DiME and other industry leaders to develop a package of resources that promotes best practices across the industry, such as the tracking of diversity-related data via a “Diversity Dashboard” and building trust among marginalized communities through local partnerships. Each resource is informed by DiME’s three-step process, fully vetted and enhanced by Lightship and other experts:

These resources allow you to approach your clinical trials with confidence, knowing that the priorities and tactics behind your overall strategy covers all four levels of engagement: notify, solicit, integrate, and support. You will have provided knowledge and information (NOTIFY), empowered your participants (SOLICIT), developed trust (INTEGRATE), and advanced health equity (SUPPORT), ultimately creating more person-centered clinical trials. But, what do those trials actually look like?

 Lightship, along with its collaborative partners at Acclinate (see sidebar), has been dedicated to a people-focused approach to clinical research from the very beginning, so it should come as no surprise that our idea of “person-centered trials” is fully realized and established. Person-centered trials are the only types of trials capable of addressing present disparities, and these trials are defined by three basic tenets: access, choice, and equity.

Unfortunately, these areas of consideration, along with the needs of many REMGs, are often neglected in the face of a pressing timeline or budget, which is likely why 86% of clinical trials do not meet their recruitment targets. Of course, digitization is an excellent avenue for addressing these disparities, but it is only the beginning. Highly specialized expertise, diverse leadership, and a deep, practical understanding of different socioeconomic groups are vital to any successful implementation. Achieving this level of understanding is no small feat, and it requires those executing clinical trials to ask some very difficult questions:

Does my training emphasize cultural sensitivity?

Is my communication being customized to the community?

Answering YES to these questions means you are building a system that organically supports and creates person-centric clinical trials.

Acclinate’s NOWINCLUDED™ engagement platform and e-DICT™ predictive analytics are the perfect complement to Lightship’s tailored approach to clinical trial execution that creates more access, choice, and equity. As such, both organizations are actively teaming up on ongoing projects in the United States to generate meaningful engagement within diverse groups of highly representative patients.

Clinical trials need more diversity. It can’t be said enough. However, as Benjamin Franklin once wrote, “Well done is better than well said.” In order to facilitate a greater level of action, Lightship, Acclinate, DiME, and clinical research organizations around the world have put together a comprehensive collection of resources and digital tools that make transitioning to a more inclusive and person-centric approach as simple and straightforward as possible. The time to take action is now, and those who take action right away will be better prepared to execute their clinical trials well into the future. They will build trust within their communities and better understand each patient, all while producing more authentic and useful data sets. 
 
 Join us in shining a light on clinical research disparity. Access resources that will confidently guide your trial design toward a more inclusive, diverse, and equitable approach.

1 Algeria, M., Sudd, S., & Steinberg, B., et al.  Reporting of Participant Race, Sex, and Socioeconomic Status in Randomized Clinical Trials in General Medical Journals, 2015 vs 2019. Jamal Network Open. Published 2021 May. 

2 National Institute of Diabetes and Digestive Kidney Diseases. Race, Ethnicity, & Kidney Disease. U.S. Department of Health and Human Services. Last reviewed 2014 March.

3 Lucas, J., & Villarroel, M.  Telemedicine Use Among Adults: United States, 2021. Centers for Disease Control and Prevention. Published 2022 Oct. 

Research That Represents: DiME, Lightship, & Acclinate Collaborate to Support Inclusivity

Join Define Ventures' life sciences forum, Patient Centricity Meets Clinical Research: Next Gen Models in Pharma Innovation  and David MacMurchy, CEO of Lightship on Sept. 12th at 9am PT. During this panel, we will be unpacking how technology and consumer-first thinking can be implemented by sponsors, CROs, and startups to drive value for patients and the broader pharma ecosystem.

Patient Centricity Meets Clinical Research: Next Gen Models in Pharma Innovation

Lightship co-founder Samantha Eells was  featured in the Women In Pharma supplement of International Clinical Trials (Samedan Ltd). Click through for a thoughtful discussion about the impact of decentralization on clinical trial diversity.

Diversity, Digitalisation, and Decentralisation

Clinical trials play a pivotal role in advancing medicine and public health. However, traditional clinical trials often fail to provide adequate access and representation for diverse populations. In the latest episode of the HealthBiz Podcast, Samantha Eells — co-founder of Lightship — discussed her journey to revolutionizing clinical trials and improving the patient experience. Lightship aims to make clinical trials more accessible and patient-centric, with a focus on addressing health disparities.

News

Follow us